News | April 06, 2022
Revenue growth to moderate, non-Covid-19 revenue to drive profitability
Ind-Ra maintains a neutral outlook for healthcare in FY23
Ind-Ra maintains a neutral outlook for healthcare in FY23
The kidney swap transplant procedure provides a solution to a critical shortage of compatible kidneys for patients suffering from kidney failures in India
The new facility is scheduled to start operation in the first half of 2024
Support for bioprocess, cell and gene therapy, and industry 4.0 initiatives
Aveir VR is specifically designed to be retrieved when therapy needs to evolve or the device needs to be replaced
New high-throughput, no-wash assays contribute to the development, manufacture and quality control of safer, more effective biotherapeutics
Lupin is committed to providing new affordable treatment options to healthcare providers and patients
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
It is currently available in tablet and injectable dosage forms
It also secures US $ 10 million for US launch and commercialization
Subscribe To Our Newsletter & Stay Updated
